Raymond James & Associates’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-41,068
| Closed | -$2.12M | – | 4136 |
|
|
2022
Q3 | $2.12M | Sell |
41,068
-242,552
| -86% | -$10M | ﹤0.01% | 1925 |
|
|
2022
Q2 | $7.03M | Sell |
283,620
-11,213
| -4% | -$247K | 0.01% | 1179 |
|
|
2022
Q1 | $7.39M | Buy |
294,833
+16,995
| +6% | +$478K | 0.01% | 1241 |
|
|
2021
Q4 | $10.1M | Sell |
277,838
-77,352
| -22% | -$2.72M | 0.01% | 1103 |
|
|
2021
Q3 | $6.07M | Buy |
355,190
+4,904
| +1% | +$76.4K | 0.01% | 1375 |
|
|
2021
Q2 | $4.69M | Buy |
350,286
+82,679
| +31% | +$2.04M | ﹤0.01% | 1531 |
|
|
2021
Q1 | $13.7M | Buy |
267,607
+39,204
| +17% | +$2.36M | 0.01% | 855 |
|
|
2020
Q4 | $14.1M | Buy |
228,403
+146,524
| +179% | +$8.39M | 0.02% | 771 |
|
|
2020
Q3 | $4.49M | Buy |
81,879
+18,242
| +29% | +$982K | 0.01% | 1289 |
|
|
2020
Q2 | $3.66M | Buy |
63,637
+6,634
| +12% | +$361K | ﹤0.01% | 1377 |
|
|
2020
Q1 | $2.29M | Buy |
57,003
+25,989
| +84% | +$1.1M | ﹤0.01% | 1491 |
|
|
2019
Q4 | $1.23M | Buy |
31,014
+11,247
| +57% | +$197K | ﹤0.01% | 2149 |
|
|
2019
Q3 | $134K | Buy |
19,767
+4,943
| +33% | +$37.1K | ﹤0.01% | 3355 |
|
|
2019
Q2 | $138K | Buy |
14,824
+950
| +7% | +$11K | ﹤0.01% | 3353 |
|
|
2019
Q1 | $193K | Buy |
13,874
+1,700
| +14% | +$19.4K | ﹤0.01% | 3252 |
|
|
2018
Q4 | $133K | Buy |
+12,174
| New | +$128K | ﹤0.01% | 3253 |
|
Other funds holding CCXI
Raymond James & Associates's CCXI Position: Q4 2022 in Review
Raymond James & Associates sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 41,068 shares — an estimated $2.12M sold.
Raymond James & Associates first reported a position in CCXI in Q4 2018 and held it in 16 quarters. The position peaked at $14.1M in Q4 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Raymond James & Associates reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Raymond James & Associates sold 41,068 ChemoCentryx, Inc. shares in Q4 2022, an estimated $2.12M.
- Raymond James & Associates first reported a position in ChemoCentryx, Inc. in Q4 2018 and held it in 16 quarters.
- Raymond James & Associates's ChemoCentryx, Inc. position peaked at $14.1M in Q4 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.